Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman

Serina Therapeutics, Inc.

First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).
Warrants if fully exercised could add up to $33.3M; total potential funds ~$63.3M to extend runway into 2H 2027.
Proceeds to fund SER-252 registrational trial for advanced Parkinson's; first patient dosed in SAD study.
Greg Bailey, M.D., lead investor, appointed Co-Chairman of Board; existing convertible note amended to eliminate further borrowing.

item 1.01item 3.02item 5.02item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.